-
1
-
-
14944385553
-
Global cancer statistics, 2002
-
Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
-
(2005)
CA Cancer J Clin
, vol.55
, pp. 74-108
-
-
Parkin, D.M.1
Bray, F.2
Ferlay, J.3
Pisani, P.4
-
2
-
-
33646568784
-
Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world
-
Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24:2137-2150.
-
(2006)
J Clin Oncol
, vol.24
, pp. 2137-2150
-
-
Kamangar, F.1
Dores, G.M.2
Anderson, W.F.3
-
3
-
-
33645286738
-
Management of hepatocellular carcinoma in Japan
-
Okita K: Management of hepatocellular carcinoma in Japan. J Gastroenterol 2006; 41:100-106.
-
(2006)
J Gastroenterol
, vol.41
, pp. 100-106
-
-
Okita, K.1
-
4
-
-
0036754637
-
Combination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma
-
DOI 10.1016/S0002-9610(02)00933-9, PII S0002961002009339
-
Kamada K, Kitamoto M, Aikata H, et al: Combination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma. Am J Surg 2002; 184:284-290. (Pubitemid 35279301)
-
(2002)
American Journal of Surgery
, vol.184
, Issue.3
, pp. 284-290
-
-
Kamada, K.1
Kitamoto, M.2
Aikata, H.3
Kawakami, Y.4
Kono, H.5
Imamura, M.6
Nakanishi, T.7
Chayama, K.8
-
5
-
-
0036237822
-
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma
-
Lo CM, Ngan H, Tso WK, et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35:1164-1171
-
(2002)
Hepatology
, vol.35
, pp. 1164-1171
-
-
Lo, C.M.1
Ngan, H.2
Tso, W.K.3
-
6
-
-
0029745063
-
Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer
-
Rossi S, Di Stasi M, Buscarini E, et al: Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR Am J Roentgenol 1996; 167:759-768.
-
(1996)
AJR Am J Roentgenol
, vol.167
, pp. 759-768
-
-
Rossi, S.1
Di Stasi, M.2
Buscarini, E.3
-
7
-
-
0033556688
-
Combined transcatheter arterial chemoembolization and local radio-therapy of unresectable hepatocellular carcinoma
-
Seong J, Keum KC, Han KH, et al: Combined transcatheter arterial chemoembolization and local radio-therapy of unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 1999; 43:393-397.
-
(1999)
Int J Radiat Oncol Biol Phys
, vol.43
, pp. 393-397
-
-
Seong, J.1
Keum, K.C.2
Han, K.H.3
-
8
-
-
0028270011
-
Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system
-
Iwamiya T, Sawada S, Ohta Y: Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system. Cancer Chemother Pharmacol 1994; 33 Suppl:S134-138.
-
(1994)
Cancer Chemother Pharmacol
, vol.33
, Issue.SUPPL.
-
-
Iwamiya, T.1
Sawada, S.2
Ohta, Y.3
-
9
-
-
0141743490
-
Radiofrequency ablation in the treatment of small hepatocellular carcinomas: Comparison of the radiofrequency effect with and without chemoembolization
-
Kitamoto M, Imagawa M, Yamada H, et al: Radiofrequency ablation in the treatment of small hepatocellular carcinomas: comparison of the radiofrequency effect with and without chemoembolization. AJR Am J Roentgenol 2003; 181:997-1003.
-
(2003)
AJR Am J Roentgenol
, vol.181
, pp. 997-1003
-
-
Kitamoto, M.1
Imagawa, M.2
Yamada, H.3
-
10
-
-
67650725801
-
Transarterial infusion chemotherapy using cisplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma
-
Kawaoka T, Aikata H, Takaki S, et al: Transarterial infusion chemotherapy using cisplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma. Cardiovasc Intervent Radiol 2009; 32:687-694.
-
(2009)
Cardiovasc Intervent Radiol
, vol.32
, pp. 687-694
-
-
Kawaoka, T.1
Aikata, H.2
Takaki, S.3
-
11
-
-
0032898237
-
Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials
-
Llovet JM, Bustamante J, Castells A, et al: Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29:62-67.
-
(1999)
Hepatology
, vol.29
, pp. 62-67
-
-
Llovet, J.M.1
Bustamante, J.2
Castells, A.3
-
12
-
-
27744531789
-
Natural history of untreated nonsurgical hepatocellular carcinoma
-
DOI 10.1111/j.1572-0241.2005.00229.x
-
Yeung YP, Lo CM, Liu CL, et al: Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol 2005; 100:1995-2004. (Pubitemid 43919392)
-
(2005)
American Journal of Gastroenterology
, vol.100
, Issue.9
, pp. 1995-2004
-
-
Yeung, Y.P.1
Lo, C.M.2
Liu, C.L.3
Wong, B.C.4
Fan, S.T.5
Wong, J.6
-
13
-
-
0031782818
-
A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients: The Cancer of the Liver Italian Program (CLIP) investigators
-
A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28:751-755.
-
(1998)
Hepatology
, vol.28
, pp. 751-755
-
-
-
14
-
-
33846630414
-
Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma
-
Uka K, Aikata H, Takaki S, et al: Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol 2007; 13:414-420.
-
(2007)
World J Gastroenterol
, vol.13
, pp. 414-420
-
-
Uka, K.1
Aikata, H.2
Takaki, S.3
-
15
-
-
0034526714
-
Advanced hepatocellular carcinoma with distant metastases, successfully treated by a combination therapy of alpha-interferon and oral tegafur/uracil
-
Miyamoto A, Umeshita K, Sakon M, et al: Advanced hepatocellular carcinoma with distant metastases, successfully treated by a combination therapy of alpha-interferon and oral tegafur/uracil. J Gastroenterol Hepatol 2000; 15:1447-1451.
-
(2000)
J Gastroenterol Hepatol
, vol.15
, pp. 1447-1451
-
-
Miyamoto, A.1
Umeshita, K.2
Sakon, M.3
-
16
-
-
32944477776
-
Complete disappearance of metastatic lung tumors and mediastinal lymphnode in a case of hepatocellular carcinoma treated by low-dose 5-fluorouracil/cisplatin therapy
-
Anami Y, Oguma S, Matsuda Y, et al: Complete disappearance of metastatic lung tumors and mediastinal lymphnode in a case of hepatocellular carcinoma treated by low-dose 5-fluorouracil/cisplatin therapy. Gan To Kagaku Ryoho 2005; 32:1977-1980.
-
(2005)
Gan to Kagaku Ryoho
, vol.32
, pp. 1977-1980
-
-
Anami, Y.1
Oguma, S.2
Matsuda, Y.3
-
17
-
-
0037315472
-
Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma
-
Patt YZ, Hassan MM, Lozano RD, et al: Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 2003; 21:421-427.
-
(2003)
J Clin Oncol
, vol.21
, pp. 421-427
-
-
Patt, Y.Z.1
Hassan, M.M.2
Lozano, R.D.3
-
18
-
-
13444257368
-
A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma
-
Ikeda M, Okusaka T, Ueno H, Takezako Y, Morizane C: A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. Cancer 2005; 103:756-762.
-
(2005)
Cancer
, vol.103
, pp. 756-762
-
-
Ikeda, M.1
Okusaka, T.2
Ueno, H.3
Takezako, Y.4
Morizane, C.5
-
19
-
-
49849086361
-
Combination therapy of oral fluoropyrimidine anticancer drug S-1 and interferon alpha for HCC patients with extrahepatic metastases
-
Uka K, Aikata H, Mori N, et al: Combination therapy of oral fluoropyrimidine anticancer drug S-1 and interferon alpha for HCC patients with extrahepatic metastases. Oncology 2008; 75:8-16.
-
(2008)
Oncology
, vol.75
, pp. 8-16
-
-
Uka, K.1
Aikata, H.2
Mori, N.3
-
20
-
-
42149116298
-
Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis
-
Nakamura M, Nagano H, Marubashi S, et al: Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis. Cancer 2008; 112:1765-1771.
-
(2008)
Cancer
, vol.112
, pp. 1765-1771
-
-
Nakamura, M.1
Nagano, H.2
Marubashi, S.3
-
21
-
-
0029835349
-
Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators
-
Shirasaka T, Shimamato Y, Ohshimo H, et al: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7:548-557.
-
(1996)
Anticancer Drugs
, vol.7
, pp. 548-557
-
-
Shirasaka, T.1
Shimamato, Y.2
Ohshimo, H.3
-
22
-
-
0030942752
-
A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein
-
Ando E, Yamashita F, Tanaka M, Tanikawa K: A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer 1997; 79:1890-1896.
-
(1997)
Cancer
, vol.79
, pp. 1890-1896
-
-
Ando, E.1
Yamashita, F.2
Tanaka, M.3
Tanikawa, K.4
-
23
-
-
0036682065
-
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: Analysis of 48 cases
-
Ando E, Tanaka M, Yamashita F, et al: Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002; 95:588-595.
-
(2002)
Cancer
, vol.95
, pp. 588-595
-
-
Ando, E.1
Tanaka, M.2
Yamashita, F.3
-
24
-
-
9144268371
-
Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis
-
Lai YC, Shih CY, Jeng CM, et al: Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2003; 9:2666-2670.
-
(2003)
World J Gastroenterol
, vol.9
, pp. 2666-2670
-
-
Lai, Y.C.1
Shih, C.Y.2
Jeng, C.M.3
-
25
-
-
0020396015
-
Toxicity and response criteria of the Eastern Cooperative Oncology Group
-
Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649-655.
-
(1982)
Am J Clin Oncol
, vol.5
, pp. 649-655
-
-
Oken, M.M.1
Creech, R.H.2
Tormey, D.C.3
-
26
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors
-
European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
-
27
-
-
33646383886
-
Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion
-
Obi S, Yoshida H, Toune R, et al: Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106:1990-1997.
-
(2006)
Cancer
, vol.106
, pp. 1990-1997
-
-
Obi, S.1
Yoshida, H.2
Toune, R.3
-
28
-
-
26944439521
-
Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression
-
Ota H, Nagano H, Sakon M, et al: Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 2005; 93:557-564.
-
(2005)
Br J Cancer
, vol.93
, pp. 557-564
-
-
Ota, H.1
Nagano, H.2
Sakon, M.3
-
29
-
-
0037080269
-
Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches
-
DOI 10.1002/cncr.10246
-
Sakon M, Nagano H, Dono K, et al: Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 94:435-442. (Pubitemid 34081374)
-
(2002)
Cancer
, vol.94
, Issue.2
, pp. 435-442
-
-
Sakon, M.1
Nagano, H.2
Dono, K.3
Nakamori, S.4
Umeshita, K.5
Yamada, A.6
Kawata, S.7
Imai, Y.8
Iijima, S.9
Monden, M.10
-
30
-
-
35148870112
-
Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma
-
Uka K, Aikata H, Takaki S, et al: Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma. Liver Int 2007; 27:1209-1216.
-
(2007)
Liver Int
, vol.27
, pp. 1209-1216
-
-
Uka, K.1
Aikata, H.2
Takaki, S.3
-
31
-
-
35448994259
-
Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma
-
Uka K, Aikata H, Takaki S, et al: Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. J Gastroenterol 2007; 42:845-853.
-
(2007)
J Gastroenterol
, vol.42
, pp. 845-853
-
-
Uka, K.1
Aikata, H.2
Takaki, S.3
-
32
-
-
0022886092
-
Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma ceUs
-
Scanlon KJ, Newman EM, Lu Y, Priest DG: Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma ceUs. Proc Natl Acad Sci U S A 1986; 83:8923-8925.
-
(1986)
Proc Natl Acad Sci U S A
, vol.83
, pp. 8923-8925
-
-
Scanlon, K.J.1
Newman, E.M.2
Lu, Y.3
Priest, D.G.4
-
33
-
-
0027285520
-
Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo
-
Shirasaka T, Shimamoto Y, Ohshimo H, Saito H, Fukushima M: Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 1993; 32:167-172.
-
(1993)
Cancer Chemother Pharmacol
, vol.32
, pp. 167-172
-
-
Shirasaka, T.1
Shimamoto, Y.2
Ohshimo, H.3
Saito, H.4
Fukushima, M.5
-
34
-
-
40749153540
-
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial
-
Koizumi W, Narahara H, Hara T, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9:215-221.
-
(2008)
Lancet Oncol
, vol.9
, pp. 215-221
-
-
Koizumi, W.1
Narahara, H.2
Hara, T.3
-
35
-
-
9744222663
-
S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: A multi-institutional phase II trial
-
Ichinose Y, Yoshimori K, Sakai H, et al: S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res 2004; 10:7860-7864.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 7860-7864
-
-
Ichinose, Y.1
Yoshimori, K.2
Sakai, H.3
-
36
-
-
0034125357
-
Induction of thymidine Phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, foUnic acid and interferon alpha
-
Braybrooke JP, Propper DJ, O'Byrne KJ, et al: Induction of thymidine Phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, foUnic acid and interferon alpha. Br J Cancer 2000; 83:219-224.
-
(2000)
Br J Cancer
, vol.83
, pp. 219-224
-
-
Braybrooke, J.P.1
Propper, D.J.2
O'Byrne, K.J.3
-
37
-
-
0025293764
-
Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A review
-
Wadler S, Schwartz EL: Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 1990; 50:3473-3486.
-
(1990)
Cancer Res
, vol.50
, pp. 3473-3486
-
-
Wadler, S.1
Schwartz, E.L.2
-
38
-
-
63649164307
-
Successful treatment of pulmonary metastases associated with advanced hepatocellular carcinoma by systemic 5-fluorouracil combined with interferon-alpha in a hemodialysis patient
-
Katamura Y, Aikata H, Kimura Y, et al: Successful treatment of pulmonary metastases associated with advanced hepatocellular carcinoma by systemic 5-fluorouracil combined with interferon-alpha in a hemodialysis patient. Hepatol Res 2009; 39:415-420.
-
(2009)
Hepatol Res
, vol.39
, pp. 415-420
-
-
Katamura, Y.1
Aikata, H.2
Kimura, Y.3
-
39
-
-
67349198077
-
Activation of Wnt/beta-catenin signalalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma
-
Noda T, Nagano H, Takemasa I, et al: Activation of Wnt/beta-catenin signalalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. Br J Cancer 2009; 100:1647-1658.
-
(2009)
Br J Cancer
, vol.100
, pp. 1647-1658
-
-
Noda, T.1
Nagano, H.2
Takemasa, I.3
-
40
-
-
1642375906
-
The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatoceUular carcinoma and its predictable factors
-
Kogure T, Ueno Y, Iwasaki T, Shimosegawa T: The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatoceUular carcinoma and its predictable factors. Cancer Chemother Pharmacol 2004; 53:296-304.
-
(2004)
Cancer Chemother Pharmacol
, vol.53
, pp. 296-304
-
-
Kogure, T.1
Ueno, Y.2
Iwasaki, T.3
Shimosegawa, T.4
-
41
-
-
0032837081
-
Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves
-
Nishiyama M, Yamamoto W, Park JS, et al: Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res 1999; 5:2620-2628.
-
(1999)
Clin Cancer Res
, vol.5
, pp. 2620-2628
-
-
Nishiyama, M.1
Yamamoto, W.2
Park, J.S.3
-
42
-
-
47949116252
-
Sorafenib in advanced hepatocellular carcinoma
-
Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390.
-
(2008)
N Engl J Med
, vol.359
, pp. 378-390
-
-
Llovet, J.M.1
Ricci, S.2
Mazzaferro, V.3
|